HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: In addition to its application in salvage regimens, one clinical trial found that continuing treatment with romidepsin in patients with stable disease (SD) could provide clinical benefits, supporting the application of HDAC inhibitors as maintenance therapy in PTCL.